BioSpace News Archive

Policy

Allergan Sues Pfizer Over Opioid Drugs

Allergan is suing Pfizer over morphine-based opioid drugs, Kadian, that Allergan acquired in December 2008. Read more if you wish to know more about this matter.

August 3, 2018
·
3 min read
·
Mark Terry
Drug Development

A Day After Second-Quarter Report, Cellectis Appoints New SVP and Deputy CMO

Cellectis announced it had appointed Stefan Scherer to the role of senior vice president Clinical Development and deputy chief medical officer.

August 3, 2018
·
2 min read
·
Mark Terry
Drug Development

Navitor Appoints New CEO

Navitor Pharmaceuticals, headquartered in Cambridge, Massachusetts, announced that Thomas E. Hughes will be the company’s new chief executive officer.

August 3, 2018
·
3 min read
·
Mark Terry
Business

A Roundup of Major Q2 Reports: Biogen, AstraZeneca, Pfizer and More

The last two weeks have marked the second-quarterly financial report by numerous biopharma companies. Here’s a quick look at some of the major ones.

August 3, 2018
·
6 min read
·
Mark Terry
Drug Development

FDA Action Alert: DURECT, Vertex, Alnylam, and Regeneron

Now that July is over, the U.S. Food and Drug Administration (FDA) appears to be back in full swing with a full docket of drug decisions to make. There are four therapeutics with PDUFA dates this week involving six biopharma companies. Here’s a look.

August 3, 2018
·
2 min read
·
Mark Terry
Drug Development

Impact Therapeutics Raises $30 Million in Series C

Impact Therapeutics, headquartered in Nanjing, China, completed a Series C financing round worth $30 million. The round was led by Decheng Capital with participating from Lilly Asian Ventures (LAV).

August 3, 2018
·
3 min read
·
Mark Terry
Drug Development

Celtaxsys’ Phase II Cystic Fibrosis Trial Fails, Despite Positive Spin

Atlanta-based Celtaxsys reported results from its Phase II EMPIRE-CF clinical trial of acebilustat for cystic fibrosis (CF), putting a positive spin on what looks to be a failed clinical trial.

August 3, 2018
·
3 min read
·
Mark Terry
Deals

In Second Big Dermatology Deal this Week, Almirall Buys 5 Products from Allergan

Almirall, headquartered in Barcelona, Spain, announced it is buying five dermatology products from Allergan. Those include Aczone (dapsone), Tazorac (tazarotene), Azelex (azelaic acid), Cordran Tape (fludroxycortide) and Seysara (sarecycline).

August 3, 2018
·
2 min read
·
Mark Terry
Business

Teva Pharma Q2 Revenues Drop 18%

Israel-based Teva Pharmaceutical’s second-quarter financial report led off with a dramatic 18 percent drop in quarterly revenue compared to the same period the year before. The company reported second-quarter sales of $4.7 billion.

August 3, 2018
·
3 min read
·
Mark Terry
Business

GrowLife, Inc. Reports Over 131% Year-Over-Year Revenue Growth in Second Quarter 2018 Financial Results and Operational Ramp-Up Highlights Update

GrowLife, Inc. announced financial results for the quarter ending June 30, 2018, and provided an overview of recent operational highlights.

August 3, 2018
·
6 min read